PeptideEmergingMitochondrial

SS-31 (Elamipretide)

Typical dose

5–10 mg

once daily · SubQ

Half-life

~1–3 hours

What is SS-31 (Elamipretide)?

Mitochondria-targeting peptide that binds cardiolipin on the inner mitochondrial membrane. Restores cellular energy production.

How SS-31 (Elamipretide) works

Selectively concentrates in the inner mitochondrial membrane and binds cardiolipin, stabilizing cristae structure, reducing ROS production, and restoring ATP synthesis.

Benefits & uses

Common uses: Mitochondrial dysfunction, aging, heart failure, ischemia-reperfusion injury, cellular energy restoration.

SS-31 (Elamipretide) dosage

Typical dose: Typical: 5–10 mg/day SubQ. 4–8 weeks.

SS-31 (Elamipretide) half-life

~1–3 hours (SubQ)

SS-31 (Elamipretide) side effects

Generally well-tolerated. Injection site reactions. Limited human safety data.

Injection site pain or redness
Limited human clinical data — monitoring recommended
Expensive and access-limited research compound

Preparation & storage

Preparation: Mix a 10 mg vial with 2 mL bac water → 5 mg/mL. A 5 mg dose = 1 mL = 100 units.
Reconstitution: Reconstitute a 10 mg vial with 2 mL BAC water → 5 mg/mL. A 5 mg dose = 1 mL = 100 units on a U-100 syringe.
Storage: Lyophilized: refrigerate (2–8 °C). Reconstituted: refrigerate, use within 14–21 days. Protect from light.

SS-31 (Elamipretide) interactions

with MOTS-c
Compatible
MOTS-c boosts mitochondrial biogenesis while SS-31 (Elamipretide) protects the inner mitochondrial membrane — complementary pathways for cellular energy.
Timing: Stack daily; MOTS-c morning, SS-31 evening or split dosing
with NAD+
Compatible
Both target mitochondrial dysfunction through different pathways (SS-31 via cardiolipin, NAD+ via sirtuins) — strong synergy for cellular energy restoration.
Timing: Administer SS-31 SubQ; NAD+ IV or SubQ separately; can be same-day protocol